Navigation Links
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Date:12/12/2012

ST. LOUIS, Dec. 12, 2012 /PRNewswire/ -- K-V Pharmaceutical Company ("K-V" or "the Company") today announced that it has received a commitment from lenders led by an affiliate of Silver Point Finance LLC for $85 million in senior secured post-petition debtor-in-possession ("DIP") financing, which the Company intends to use to, among other things, satisfy the terms of its recently filed settlement agreement with Hologic, Inc. ("Hologic Settlement"), provide additional financial flexibility during the pendency of the Company's Chapter 11 proceeding and fund certain payments under a proposed reorganization plan.  The new DIP financing, the Hologic Settlement and the reorganization plan (and related disclosure statement)  are each subject to approval of the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding.

The Hologic Settlement confirms K-V's continued ownership of Makena® and will resolve all bankruptcy related disputes between K-V and Hologic, and provides for mutual releases of all claims between the parties. 

Under the proposed reorganization plan, K-V expects to emerge from Chapter 11 with its entire product portfolio, including Makena®, Clindesse®, Gynazole-1® and Evamist®.  The Company has provided and is committed to continue to provide its women's health care products without interruption to meet the needs of the health care providers and patients it serves.

Prior to the funding of the DIP financing facility, K-V intends to file with the Bankruptcy Court a proposed reorganization plan, a related disclosure statement, and a plan support agreement (PSA) with an ad hoc group of senior secured noteholders.  The principal terms of the proposed reorganization plan are contained in a plan term sheet filed with the motion to approve the DIP financing filed with the Bankruptcy Court, which together with other documents from the Chapter
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer ... agreement whereby the institutional investors will have the option ... Company up to $4.93M in near term funding, pending ... the restructured terms and subject to certain market conditions, ... result in a larger influx of capital to fund ...
(Date:6/2/2015)... 2, 2015 /CNW/ - Shell today celebrated the North American ... category with an exhibit the size of a city ... demonstrations for media and the public, and special appearances ... Premium Gasoline provides the best total engine protection by ... wear, gunk and corrosion. "With the launch ...
(Date:6/2/2015)... and TORONTO , June 2, ... TSX: APS), a clinical-stage company developing new therapeutics that ... the U.S. Food and Drug Administration (FDA) has granted ... treatment of acute myeloid leukemia (AML). APTO-253, a first-in-class ... product candidate in a Phase Ib clinical trial in ...
(Date:6/2/2015)... June 02, 2015 Global Stem Cells ... distributor for Bioquark, Inc.’s biologic products for the regeneration and ... latest in Global Stem Cells Group’s ambitious expansion plans in ... demand for access to regenerative medicine and stem cell therapies. ... development of biologics that have the ability to alter the ...
Breaking Biology Technology:TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3
... (Nasdaq: MSHL ), an oncology company focused on ... today that Charles Baltic, Managing Director and Co-Head of Healthcare ... of directors. The appointment of Mr. Baltic increases the number ... directors to five. "On behalf of the entire ...
... /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... biopharmaceutical companies in the People,s Republic of China, today ... annual list of Asia,s "200 Best Under a Billion" ... to the same list for the year 2009. ...
... Conn., Oct. 24, 2011 Modern Plastics, one of ... and medical-grade plastics, has become ISO 13485-2003 certified for ... Film and Resin. "This is an ... commitment to service and quality," said Bing J. Carbone, ...
Cached Biology Technology:Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3
(Date:6/1/2015)... June 1, 2015 According to ... Sensing Market by Technology (Touch-based & Touchless), Application (Consumer ... & by Geography - Global Forecast to 2020", published ... is expected to reach $23.55 Billion by 2020, at ... Browse 83 market data T ables ...
(Date:6/1/2015)... 2015 According to a ... by Application (Government, Military & Defense, Healthcare, Banking ... Security), Technology (Face Recognition, Fingerprint Recognition, Iris Recognition, ... and Others), Function (Contact and Non-Contact) & Geography ... Europe , APAC, Row) - Global Forecast ...
(Date:5/29/2015)... , May 28, 2015 Research and ... of the "Facial Recognition Market by Solution, ... Global Forecast to 2020" report to their ... seen facial recognition technology become more efficient and ... gain traction and investment from the commercial sector. ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... Genetic disease risk differences between one individual and another are ... the genes themselves, or else differences at the heart of ... By gene regulation we mean the decision that the cell ... activate or suppress the expression of a gene. In theory, ...
... those with HIV have recognized a relationship between how faithfully ... virus is to develop drug resistance. More recently, research has ... and resistance is different for each of the drugs that ... New research conducted by Harvard scientists could help explain ...
... ARBOR, Mich. Scientists have restored the sense of smell ... a hopeful sign for people who can,t smell anything from ... in curing congenital anosmia -- the medical term for lifelong ... other conditions that also stem from problems with the cilia. ...
Cached Biology News:A new light shed on genetic regulation's role in the predisposition to common diseases 2Design help for drug cocktails 2Design help for drug cocktails 3Can't smell anything? This discovery may give you hope 2Can't smell anything? This discovery may give you hope 3
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: